Zealand Pharma: higher royalty payments in second quarter

(CercleFinance.com) - Zealand Pharma reported a 85% rise in royalty payments over the second quarter, with sales of Soliqua/Suliqua by Sanofi leaping 260% over the same period last year.


The Danish biotech company said it will receive quarterly royalty revenues from Sanofi's sales of Soliqua/Suliqua amounting to 11.5 million Danish kronor (1.8 million dollars).

The company, which develops and markets drugs for metabolic and gastrointestinal diseases, will also receive 3.6 million Danish kronor (about 600,000 dollars) from Lyxumia/Adlyxin sales.

In comparison, Zealand reported royalty revenue from Sanofi's sales of Lyxumia/Adlyxin of 5.2 million Danish kronor in the second quarter of 2017, and just 3.9 million Danish kronor from Suliqua/Soliqua.

The shares were up 1.9% at 94.9 Danish kronor in Copenhagen after these figures were released.

Copyright (c) 2018 CercleFinance.com. All rights reserved.